The FDA approved SIR-Spheres Y-90 resin microspheres for unresectable liver cancer, the only radioembolization approved in ...

The FDA approved Y-90 resin microspheres for the treatment of unresectable hepatocellular carcinoma, according to a press ...

Chennai: In a meaningful step towards transforming liver cancer care in India, Apollo Proton Cancer Centre (APCC), Chennai, ...

Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology solutions, today announced that the U.S. Food ...

Approval was based on results from the DOORwaY90 trial, which demonstrated a 98.5% overall response rate and 100% local tumor control in patients treated with the SIR-Spheres Y-90 resin microspheres ...

Sirtex Medical’s SIR-Spheres Y-90 resin microspheres receive US FDA nod to treat unresectable hepatocellular carcinoma: Woburn, Massachusetts Tuesday, July 8, 2025, 17:00 Hrs [I ...

The FDA approves SIR-Spheres Y-90 microspheres for treating unresectable hepatocellular carcinoma, showcasing impressive ...

Sirtex Medical announced that the FDA has approved the company’s SIR-Spheres yttrium-90 (Y90) resin microspheres for the trea ...

The FDA approved yttrium-90 resin microspheres (SIR-Spheres Y-90; Sirtex Medical), also known as radioembolization or selective internal radiation therapy, for inoperable hepatocellular carcinoma. The ...

The selective internal radiation therapy SIR-Spheres has been approved by the FDA for use in patients with unresectable ...